ASCO 2021 Solid Tumors – Roberto Pazo-Cid

Roberto Pazo-Cid outlines recent insights gained in terms of anti-PD-1 treatment in the setting of esophageal squamous cell carcinoma, talks about the practice-changing results obtained in the CheckMate 649 trial and the impact of PD-1 inhibition on the real-world prognosis of patients with gastric and esophageal adenocarcinoma as well as further developments regarding immune checkpoint inhibition.

Here is the full ASCO 2021 Solid Tumors report.

More posts

Load More Posts